BRCA1 and neoplasm: Ultimately, we hope to see future discovery of synthetic lethal partners for non-druggable yet incredibly high-risk CPGs, such as BRCA1/2, and to witness such discoveries’ impacts on targeted cancer therapeutics and prevention in a way that is comprehensive of different tumor types.